Peptides
Kisspeptin
Also called Kisspeptin-10 · Metastin
Kisspeptin draws interest for libido, reproductive hormones and fertility. Early human studies are promising for specific hormone and sexual-response measures, but kisspeptin-10 and kisspeptin-54 are different forms, and the tested infusions are not the same as a few weekly home injections.
Dosage & duration
Separate a user’s reported plan from a controlled infusion experiment.
One reported TRT-related plan
Reported use · unapproved regimen- Dose
- 100 mcg
- How often
- Three times weekly; route/form not verified
- How long
- Two months on, one month off proposed
An individual plan, not a demonstrated effective cycle or verified fertility treatment.
2026 kisspeptin-10 study
Published example · product-specific- Dose
- 150 nmol per hour
- How often
- Eight-hour under-skin infusion daily
- How long
- 12 days
Small healthy-men hormone study; this is an infusion rate, not a one-shot amount.
Sources: 2
The libido study used kisspeptin-54; it cannot validate this reported KP10-style plan.
Match the result to the goal
Desire, hormones and fertility need separate answers
-
Sexual desire
Early studies measured acute responses to sexual cues.
-
Hormone signals
A rise in LH, FSH or testosterone is a different outcome.
-
Fertility
Sperm and pregnancy outcomes need their own evidence.
Libido and fertility are different goals
A person can have sexual desire without normal sperm production, or fertility concerns without low desire. A laboratory arousal response is not proof of restored fertility. The endpoint should match the problem you want to understand.
What the sexual-desire study found
An acute kisspeptin-54 infusion altered sexual brain responses and increased arousal measures in men with low desire. It did not test a long-term kisspeptin-10 injection course or establish a replacement for established assessment and treatment.
Newer hormone research still depends on delivery
A small 2026 study sustained hormone responses during 12 days of daily eight-hour kisspeptin-10 infusions. That adds human evidence, but the schedule and population differ sharply from reported TRT-adjunct routines. It did not establish sperm recovery or ongoing libido benefit.
Model details: Kisspeptin · relative timing
Compare timing and buildup for this compound. The values are not blood concentrations or a measure of strength.
Shows a relative timing scenario; absolute blood concentrations are not calibrated.
Timing assumptions and sources
KP54 IV half-life is about 27.6 min; KP10 is about 3.8–4.1 min. Neither establishes SC absorption for the generic product.
One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.
- Timing half-life used
- 0.46 hours
- Absorption half-life assumed
- 0.115 hours
- Reference amount for the relative scale
- 1 mg
- Absorption half-life is assumed to be one quarter of the slower timescale (0.115 h); it is not a measured absorption parameter.
- A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
- Clarify peptide identity beside the curve; do not silently treat all kisspeptin as KP54.
- Absolute calibration requires a known peptide length, analyte, route, assay and reference dose.
- This curve does not include endogenous peptide or predict gonadotropin responses.
- Dhillo et al. 2005 kisspeptin-54 study
The healthy-male IV KP54 study is the source behind the roughly 28 min disappearance time.
- Jayasena et al. 2011 kisspeptin-10 human study
Study 5 calculated KP10 IV half-lives of 3.8 min in men and 4.1 min in women; route changes alter exposure. Kisspeptin immunoreactivity is distinct from LH.
- FDA kisspeptin-10 review 2024
The review identifies no absolute SC availability and distinguishes KP10 from KP54.
kisspeptin-relative-timing-2026-10 · version 1
Common questions
Is KP10 the same as KP54?
No. They are different kisspeptin forms with different exposure and study regimens.
Does more LH prove fertility has returned?
No. A hormone response is not a semen or pregnancy outcome.
Sources Labels, studies and notes behind this guide
Catalog evidence: Human clinical trials. This describes the type of evidence, not a clinical review of every claim.
Summary and fact source checks: 2026-10-07. This records source checking, not medical review of the whole page.
Notes on the quick facts
- Main interests
- Related, but they require different outcome measures.
- Know the form
- Do not transfer doses or results between forms.
- Delivery matters
- Not the same as occasional home injections.
- 1. Mills et al. — kisspeptin and low desire
Kisspeptin-54 IV infusion in men with hypoactive sexual desire disorder; acute laboratory sexual-response results, not a home KP10 regimen.
- 2. Yeung et al. — 12-day kisspeptin-10 study
2026 small healthy-men study: daily eight-hour SC infusions at 150 nmol/hour for 12 days sustained gonadotropin responses. No fertility or long-term libido outcome.
- 3. Dhillo et al. 2005 kisspeptin-54 study
The healthy-male IV KP54 study is the source behind the roughly 28 min disappearance time.
- 4. Jayasena et al. 2011 kisspeptin-10 human study
Study 5 calculated KP10 IV half-lives of 3.8 min in men and 4.1 min in women; route changes alter exposure. Kisspeptin immunoreactivity is distinct from LH.
- 5. FDA kisspeptin-10 review 2024
The review identifies no absolute SC availability and distinguishes KP10 from KP54.
- 6. Dhillo et al., kisspeptin-54 in healthy men
Six-men placebo-controlled IV study; LH/FSH/testosterone response and 27.6-minute plasma half-life for kisspeptin-54.
- 7. Jayasena et al., human kisspeptin-10 response and PK
Human IV study: kisspeptin-10 half-life about 3.8–4.1 minutes; responses differ by sex/menstrual phase. Not kisspeptin-54 equivalence.
- 8. Jayasena et al., kisspeptin-54 IVF proof-of-concept study
53 women received SC kisspeptin-54 within supervised IVF; egg maturation, pregnancies and live births. No active-trigger comparison and not male PCT evidence.
Related compounds and examples
Related compounds
HCG
Why people use hCG for fertility or alongside TRT, how the goals differ, and source-specific IU doses, timing, side effects and storage.
HMG (Menotropin)
HMG versus hCG for fertility: Menopur dose context, months-long treatment and why testosterone levels do not show sperm count.
Gonadorelin Acetate
Gonadorelin versus hCG on TRT: reported clinic doses, fertility expectations and why pump timing matters.